1. Scrip
  2. >>Business

Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious

 
• By Jung Won Shin

Following the start of a probe by financial authorities earlier this month into suspicions Hanmi may have leaked undisclosed information relating to the return of rights to its cancer drug olmutinib, prosecutors have raided the headquarters of the South Korean pharma to get to the bottom of the affair.

Prosecutors in South Korea have launched a probe into Hanmi Pharmaceutical Co. Ltd., raiding its headquarters in Seoul amid suspicions that a leakage of undisclosed information may have caused the sharp volatility in the company’s stock price on Sept. 30, when Hanmi announced that Boehringer Ingelheim GMBH had returned rights to its cancer drug olmutinib.

In a new statement, Hanmi apologized to its shareholders and the nation over the concerns raised by prosecutors and vowed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.